This gives hope, especially for people who live in the same house as those infected with the Coronavirus. This is shown in a Phase 3 clinical study conducted by the pharmaceutical company Roche with the US biotechnology company Regeneron. The aim was to verify whether an antibody cocktail made with casirivimab and imdevimab could help reduce the risk of infection and exposure to MERS-CoV in contacts within the family.
The study, which Roche and Regeneron conducted with the National Institute of Allergy and Infectious Diseases (NIAID), achieved its goals. And this is a relief: An injection with an antibody cocktail can reduce some of the risks associated with corona. The results showed that the cocktail reduced the risk of infection by 81 percent.
Double effect of cocktail
But that’s not all: Anyone treated with kazrifimab and imdifimab, but still infected and symptomatic, has experienced a variation in the course of the disease. The symptoms disappeared within a week compared to the subjects who swallowed the so-called placebo. It took three weeks for the symptoms to go away.
Roche now wants to make the accurate results of the study available to regulatory authorities in the USA, Europe and other countries as soon as possible.
For Lauterbach, “Game Changer”: Asthma spray can help fight corona(00:51)
Publication date: April 12, 2021, 10:01 am
Last update: April 12, 2021, 5:16 pm